Evaluation of PReimplantation embryo Aptitude for DEvelopment (EPRADE) - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Autre Publication Scientifique Année : 2021

Evaluation of PReimplantation embryo Aptitude for DEvelopment (EPRADE)

Résumé

In spring 2020, a group of researchers – investigators of a French program for clinical research in hospitals (PHRC) entitled Comprehensive Chromosomal Testing of Trophectoderm (Te) Biopsies of Blastocysts (Ctteb) to Improve Live Birth Rates After in Vitro Fertilization: A Prospective Randomized Trial, sought the opinion of the Inserm Ethics Committee (CEI) regarding their project. This was on the informal advice of the French Agency of Biomedicine (ABM), despite the Ministry of Health’s Directorate General for Healthcare Provision (DGOS) having already accepted and funded the program and before the French National Agency for the Safety of Medicines and Health Products (ANSM) had approved its performance.

Domaines

Ethique
Fichier principal
Vignette du fichier
IEC Note Eprade June 2021-EN.pdf (738.26 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-03328662 , version 1 (30-08-2021)

Identifiants

  • HAL Id : inserm-03328662 , version 1

Citer

Bernard Baertschi, Bertrand Bed’hom, Christine Dosquet, Marie Grosset, Anne Dubart-Kupperschmitt, et al.. Evaluation of PReimplantation embryo Aptitude for DEvelopment (EPRADE). 2021. ⟨inserm-03328662⟩
165 Consultations
70 Téléchargements

Partager

Gmail Facebook X LinkedIn More